Pacific Biosciences of California, Inc.
PACB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $1 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -3.3% | 7% | -5.3% | – |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 41.4% | 36.9% | -3.7% | 25.6% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -84.3% | -89.5% | -139.6% | 41.8% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -98.9% | -105.4% | -1,146.8% | 6% |
| EPS Diluted | -0.13 | -0.14 | -1.44 | 0.008 |
| % Growth | 7.1% | 90.3% | -18,801.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |